AstraZeneca recently announced that the FDA granted accelerated approval to camizestrant (Etcamah) in combination with a CDK4/6 inhibitor for adults with HR-positive/HER2-negative locally advanced or metastatic breast cancer. The indication applies when an ESR1 mutation is detected during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy using an FDA-authorized test. Approval Highlights SERENA-6 reduced the risk […]
- info-gsls@greenstafflifesciences.com
- Mon - Fri: 9.00 - 18.00 (JST)
- Accessibility